Unió Europea - espanyol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paclitaxel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - agentes antineoplásicos - la monoterapia con abraxane está indicada para el tratamiento del cáncer de mama metastásico en pacientes adultos que han fracasado en el tratamiento de primera línea para la enfermedad metastásica y para quienes la terapia estándar que contiene antraciclina no está indicada. abraxane en combinación con gemcitabina está indicada para el tratamiento de primera línea de pacientes adultos con metástasis de adenocarcinoma de páncreas. abraxane en combinación con carboplatino está indicado para el tratamiento de primera línea de la no-pequeño cáncer de pulmón de células en pacientes adultos que no son candidatos para cirugía potencialmente curativa y/o terapia de radiación.

Unió Europea - espanyol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - la talidomida - mieloma múltiple - inmunosupresores - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Unió Europea - espanyol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Unió Europea - espanyol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod clorhidrato de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - inmunosupresores - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Unió Europea - espanyol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - leucemia, mieloide, aguda - agentes antineoplásicos - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Unió Europea - espanyol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agentes antineoplásicos - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unió Europea - espanyol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agentes antineoplásicos - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Equador - espanyol - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

bristol-myers squibb pharma eeig [ie] ireland - pomalidomida 2mg - capsulas duras - cada cÁpsula dura de 2mg contiene: pomalidomida 2mg

Equador - espanyol - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

bristol-myers squibb pharma eeig [ie] ireland - pomalidomida 1,00mg - capsulas duras - cada cápsula de 1mg contiene: pomalidomida 1,00mg

Equador - espanyol - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

bristol-myers squibb pharma eeig [ie] ireland - pomalidomida 3mg - cÁpsulas duras - cada cÁpsula de 3mg contiene: pomalidomida 3mg